10/2023

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

10/2023

Oct 22, 2023, 00:11 | Blog
Maite Bourlon: Press release on CheckMate-67T study of subcutaneous Nivolumab while The European Society for Medical Oncology (ESMO) begins
Maite Bourlon, Urology Oncologist at the National Institute of Medical Sciences and Nutrition Salvador Zubirán,…
Oct 22, 2023, 00:00 | Blog
Gustaf Salford: We have received a major order of multiple linac systems from Ukraine through our partnership with the Ukrainian Ministry of Health
Gustaf Salford, President and CEO at Elekta, shared the following post by Elekta, adding the following: "This…
Oct 21, 2023, 23:53 | Blog
Peter Lebowitz: Three Phase 3 lung cancer readouts in the Presidential Symposium and 4 late-breaker presentations in genitourinary cancers
Peter Lebowitz, SVP, Global Oncology Therapeutic Area Head at Janssen/Johnson and Johnson, made the following…
Oct 21, 2023, 23:44 | Blog
Janice Cowden: We marched on Capitol Hill with Metavivor Research and Support Inc. to advocate for increased funding for Metastatic Breast Cancer
Janice Cowden, Metastatic Breast Cancer Patient Advocate, made the following post on LinkedIn "This week…
Oct 21, 2023, 21:40 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 9
We continue OncoDaily’s ‘100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social…
Oct 21, 2023, 19:39 | Blog
Nirmala Bhoo Pathy: A prerequisite to putting patients at the heart of cancer care is knowing what they need
Nirmala Bhoo Pathy, Professor of Epidemiology at the University of Malaya, shared on her LinkedIn…
Oct 21, 2023, 19:38 | Blog
Top 5 Prostate abstracts not to miss by Tian Zhang
Tian Zhang, Associate Professor specialized in GU cancers at the UT Southwestern Medical Center, shared…
Oct 21, 2023, 19:37 | Blog
Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.
Amol Akhade, Senior Consultant in Medical and Hematooncology at the Dr Hitendra Patil's Suyog Cancer…
Oct 21, 2023, 19:37 | Blog
Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.
Jose Fernando Moura, Oncologist and Principal Investigator in Solid Tumors at Real Hospital Portuguese and…
Oct 21, 2023, 19:36 | Blog
Nicola Fusco: It has been a genuine pleasure to visit the Institute Gustave Roussy
Nicola Fusco shared a post on LinkedIn: “It has been a genuine pleasure to visit…
All: 805 Posts: 231 - 240